Discover the new Chem-Impex: Where innovation starts with a bond.

Catalog Number:
35338
CAS Number:
100286-90-6
Irinotecan hydrochloride anhydrous, Topoisomerase I Inhibitor
Purity:
98 - 102% (HPLC)
Synonym(s):
CPT-11
Documents
$30.00 /25MG
Pack Size Availability Price
Request Bulk Quote
Product Information

Irinotecan hydrochloride anhydrous is a potent topoisomerase I inhibitor, primarily utilized in the treatment of various cancers, including colorectal cancer. This compound works by interfering with the DNA replication process, effectively halting the proliferation of cancer cells. Its unique mechanism of action makes it a critical component in chemotherapy regimens, often used in combination with other agents to enhance therapeutic efficacy. Researchers and healthcare professionals value Irinotecan for its ability to target rapidly dividing cells, providing a strategic advantage in cancer treatment protocols.

In addition to its established role in oncology, Irinotecan hydrochloride anhydrous is also being explored for its potential applications in other therapeutic areas, such as in combination therapies for different types of tumors. Its solubility and stability make it suitable for various formulations, enhancing its versatility in pharmaceutical development. With ongoing research into its mechanisms and applications, Irinotecan continues to hold promise for improving patient outcomes in cancer therapy.

Synonyms
CPT-11
CAS Number
100286-90-6
Purity
98 - 102% (HPLC)
Molecular Formula
C33H38N4O6·HCl
Molecular Weight
623.14
MDL Number
MFCD01862255
PubChem ID
357467
Melting Point
250 - 256 ?C
Appearance
Off-white to light yellow crystalline powder
Conditions
Store at 2 - 8 °C
General Information
Synonyms
CPT-11
CAS Number
100286-90-6
Purity
98 - 102% (HPLC)
Molecular Formula
C33H38N4O6·HCl
Molecular Weight
623.14
MDL Number
MFCD01862255
PubChem ID
357467
Melting Point
250 - 256 ?C
Appearance
Off-white to light yellow crystalline powder
Conditions
Store at 2 - 8 °C
Properties
Additional property information coming soon!
-
Safety and Regulations
Hazmat
No
Antibiotic
No
DEA-regulated
No
Warnings
-
Applications

Irinotecan hydrochloride anhydrous is widely utilized in research focused on:

  • Cancer Treatment: This compound is primarily used in chemotherapy regimens for treating colorectal cancer. It works by inhibiting topoisomerase I, an enzyme crucial for DNA replication, thereby preventing cancer cell proliferation.
  • Pharmaceutical Development: Researchers are exploring formulations that enhance the bioavailability and efficacy of irinotecan, making it a focal point in drug development studies aimed at improving cancer therapies.
  • Combination Therapies: It is often studied in combination with other anticancer agents to evaluate synergistic effects, helping to develop more effective treatment protocols for various cancers.
  • Clinical Trials: Irinotecan is frequently involved in clinical trials assessing its effectiveness and safety in different cancer types, providing valuable data that can influence treatment guidelines.
  • Research on Drug Resistance: Scientists are investigating how cancer cells develop resistance to irinotecan, which is critical for developing strategies to overcome this challenge and improve patient outcomes.

Citations